The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

A method of detecting a substance, wherein the method includes functionalizing a plurality of sensors, wherein the functionalizing the plurality of sensors comprises depositing a first material using a piezoelectrically actuated pipette system, wherein the first material includes a polymer, a receptor, and a solvent, wherein the solvent comprises dimethylformamide. The method further includes evaporating a solution of the first material, wherein a residue after the evaporation comprises a functionalized chemical. Additionally, the method includes introducing a control material to a first set of sensors of the plurality of sensors using the piezoelectrically actuated pipette system. Further, the method includes introducing a test material to a second set of sensors of the plurality of sensors using the piezoelectrically actuated pipette system, wherein the test material comprises an analyte. Moreover the method includes determining a difference between a first resonant frequency shift in the first set of sensors of the plurality of sensors and a second resonant frequency shift in the second set of sensors of the plurality of sensors.

The present invention provides a platform for in vitro or in vivo study of the correlation between a Purkinje cell-specific, circadian clock gene and ataxia, in particular, a non-human transgenic animal model induced by genetic modification to knockdown the circadian clock gene, Bmal1, which causes abnormal diurnality and loss of certain motor skills and learning ability in a subject. The present invention also relates to methods of making and using the platform for various applications. A composition including a vector carrying the Bmal1 gene for restoring expression thereof in the subject's cerebellum to potentially treat ataxia arising from the Bmal1 gene deficiency is also provided.

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

Disclosed herein are methods and compositions useful in diagnosing, prognosing, monitoring, and treatment of neurological disorders. The markers are syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin. These markers can be used alone or in combination.

The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.

The present invention relates generally to the field of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction. The present invention provides methods of diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

Methods for treating depression in, and decreasing a dose of ketamine given to, a subject in need thereof, comprising, administering a CaMKII inhibitor are provided.

The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.

A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.